Roberto Moretto

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 354 citations · Full text

Medicine, Immunology, Oncology +17

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 270 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study

Chiara Alessandra Cella, Giovanni Di Minno, Chiara Carlomagno et al. · The Oncologist · 2017 · 159 citations · Full text

Medicine, Biostatistics, Oncology +17

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Chiara Cremolini, Maria Di Bartolomeo, Alessio Amatu et al. · Annals of Oncology · 2015 · 155 citations · Full text

Medicine, Molecular Genetics, Oncology +17